Navigation Links
Schwarz's New Epilepsy Drug Reduces Seizures

An experimental epilepsy drug, lacosamide, developed by U.S firm Schwarz has found to be potential in reducing the frequency of seizures in patients// not controlled by other drugs - the company said on Monday following the results of a phase 3 trial.

The results of the 485-patient study were presented at the North American Regional Epilepsy Congress. The results proved that epileptics treated with a 200-mg dose of the drug, lacosamide, had 14.4 percent fewer seizures than those given a placebo, while patients given a 400-mg dose had 15 percent fewer seizures than placebo-treated patients. Dizziness, headache and double vision, are considered to be the two major side effects of the drug, lacosamide - the company added.

"We are delighted that lacosamide has demonstrated efficacy in a very difficult-to-treat patient population," said Iris Loew-Friedrich, a member of Schwarz' executive board.

"This trial will be submitted to the regulatory agencies in both the European Union and the (United States) as part of the marketing authorization application for lacosamide as adjunctive therapy in adults with partial seizures," Loew-Friedrich added.

Around 2.3 million Americans suffer from epileptic seizures and about 30 percent of them require two or more drugs to control the seizures, said Mike Davis, product director for Schwarz Pharma, which is being acquired by Belgian pharmaceutical group UCB SA.

It is expected that the full results from a second Phase III trial of lacosamide will be announced early next year and the drug could be on the market within the next year or so depending on the regulatory issues. – added the report.


SRI
'"/>




Page: 1

Related medicine news :

1. General Anesthesia Safe For Children On Ketogenic Diet Suffering From Epilepsy
2. Researchers Scale to assess the Severity of Epilepsy in Kids
3. Epilepsy can be predicted
4. Epilepsy Drugs Can Enhance Risk of Birth Defects
5. Epilepsy Drug Helps Diabetic Nerve Damage
6. Epilepsy Drug May Relieve Chronic Headaches
7. More Complications Seen In Women With Epilepsy
8. Epilepsy Drugs Found To Lead To Bone Loss
9. Another Use For Epilepsy Drugs
10. Epilepsy Patients Could Benefit From Pacemakers
11. Early Surgery For Treatment Of Epilepsy Questioned
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/19/2017)... PETALUMA, CA (PRWEB) , ... January 19, 2017 ... ... new Tranquility acoustic and privacy panel system. , The Tranquility privacy panel ... to a collaborative office environment. Tranquility panels help reduce noise and provide the ...
(Date:1/19/2017)... ... January 19, 2017 , ... Allegheny Health Network (AHN) officials ... seek access to the Network’s programs and services in the greater Pittsburgh region. Starting ... appointments will be offered one for that same afternoon. , AHN ...
(Date:1/19/2017)... Savannah, GA (PRWEB) , ... January 19, 2017 ... ... that offers asset protection and financial planning services to communities throughout eastern Georgia, ... the fight against heart disease. , Heart disease kills more Americans every year ...
(Date:1/19/2017)... Lawrenceville, NJ (PRWEB) , ... January 19, 2017 ... ... a locally owned insurance agency which serves Lawrenceville, New Jersey and the surrounding ... HLC. , Amyotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig's ...
(Date:1/19/2017)... San Antonio, TX (PRWEB) , ... January 19, 2017 , ... ... Pate, has for the fifth consecutive year donated money to the Triumph Over Kid ... James A. Ragan was one of those children. James saw firsthand the effect of ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... January 19, 2017 According to a study ... is set to witness a CAGR of 6.5% during the forecast ... will continue to be the leading market for cryotherapy globally ... ... emphasizing on ensuring affordable and adequate supply of gas in order ...
(Date:1/19/2017)... -- James Gilbart , ... 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ...      ... in a supplement to European Oncology & Haematology ... by James Gilbart and Axel ...
(Date:1/19/2017)... 2017 Shire plc (LSE: SHP, ... Food and Drug Administration (FDA) has acknowledged receipt of ... (NDA) for SHP465, a long-acting, triple-bead, mixed amphetamine salts ... treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is expected ... 2017, the designated Prescription Drug User Fee Act (PDUFA) ...
Breaking Medicine Technology: